Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 2/20 | 0.59 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | LYN | P07948 | 2/20 | 0.59 |
| ▸ | HCK | P08631 | 2/20 | 0.59 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | BRAF | P15056 | 15/20 | 0.51 |
| ▸ | RAF1 | P04049 | 4/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.48 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586326 | 0.93 | LYN (0.58) | INSRLCKLYNHCKSRC | |
| SCHEMBL4587746 | 0.91 | CSF1R (0.56) | INSRLCKLYNHCKSRC | |
| SCHEMBL14097772 | 0.90 | LYN (0.48) | INSRLCKLYNHCKSRC | |
| SCHEMBL4587871 | 0.88 | CSF1R (0.48) | INSRLCKLYNHCKSRC | |
| SCHEMBL4587496 | 0.86 | CSF1R (0.56) | INSRLCKLYNHCKSRC | |
| SCHEMBL3233331 | 0.86 | LYN (0.75) | INSRLCKLYNHCKSRC | |
| SCHEMBL1827695 | 0.84 | HCK (0.63) | INSRLCKLYNHCKSRC | |
| SCHEMBL14097854 | 0.84 | MAPK14 (0.47) | INSRLCKLYNHCKSRC | |
| SCHEMBL14097786 | 0.84 | LYN (0.46) | INSRLCKLYNHCKSRC | |
| SCHEMBL4586222 | 0.84 | PIKFYVE (0.57) | INSRLCKLYNHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188483-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-08-07 | — | — | US | claimed |
| US-20080188483-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-08-07 | — | — | US | disclosed |
| US-20080188483-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-08-07 | — | — | US | disclosed |
| EP-1858521-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006101783-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188483-A1 | Compounds and Compositions as Protein Kinase Inhibitors | SRC, SGK2, PTK2B | INSR 1488/4885LCK 19/4885LYN 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.